EP1565569A2 - Verfahren zum nachweis von mutationen - Google Patents
Verfahren zum nachweis von mutationenInfo
- Publication number
- EP1565569A2 EP1565569A2 EP03737328A EP03737328A EP1565569A2 EP 1565569 A2 EP1565569 A2 EP 1565569A2 EP 03737328 A EP03737328 A EP 03737328A EP 03737328 A EP03737328 A EP 03737328A EP 1565569 A2 EP1565569 A2 EP 1565569A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleic acid
- sample
- receptor
- oligo
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Definitions
- the invention relates to a method for the detection of mutations in a nucleic acid.
- a polymorphism is a variation, a genomic nucleic acid sequence that can often be found in the same place. This can involve the exchange of individual bases, a so-called point mutation, as well as small deletions, insertions and inversions, but also the reorganization of large sequence sections. In any case, the sequence is changed in one or more places compared to the wild type.
- polymorphisms are used as markers to determine the degree of relationship between two organisms by tracking the inheritance of the polymorphisms.
- the most important genetic markers include single base mutations in which one of the four nucleotides is exchanged for another and which are also called SNP (single nucleotide polymorphism).
- polymorphisms serve, on the one hand, to detect certain diseases in which genes are changed by single-base mutations, thereby triggering diseases.
- Another important field of application is the so-called HLA typing, which is used to compare the similarity of immune systems of two individuals based on the state of many loci on the HLA genes. HLA typing is primarily used to determine whether a graft will be compatible with transplants.
- Another area in which the detection of polymorphisms is important is pharmacogenomics, in which, by detecting certain polymorphisms, drug tolerance should be predictable when treating a particular patient.
- a homoduplex both strands have the same origin
- at least one of the strands hybridizes with a "foreign" strand (a probe) and forms a heteroduplex (strands of different origins).
- the heteroduplex can then open different ways can be used for detection.
- DNA sequencing can be used universally, but is very expensive for routine diagnostic tests.
- the pure screening methods can either be traced back to the principle of the different migration behavior of wild-type or mutant heteroduplexes in electrophoresis gels, or to the enzymatic digestion of heteroduplexes.
- a heteroduplex is formed from sample DNA and an oligonucleotide probe.
- the discrimination between wild type and mutant can then be achieved either by using stringent hybridization conditions or by enzymatic reactions.
- oligonucleotides are used which hybridize to the wild type under perfect buffer and temperature conditions for this sequence (perfect match) but not to the mutant (mismatch).
- the problem with this procedure is that when such tests are carried out in parallel in one approach, no conditions have to be set which are equally stringent for all analytes.
- DNA polymerase is used in PCR with sequence-specific primers (SSP) and in "mini-sequencing".
- SSP sequence-specific primers
- mini-sequencing The principle of the SSP is based on the fact that a PCR primer, which is a strand of a heteroduplex, only then through the polymerase reaction if it is a perfect match, the polymerase reaction does not take place in the event of a mismatch, which is why no PCR product can be detected.
- Mini-sequencing is a modification of SSP-PCR.
- a heteroduplex is formed which ends at the 3 'end exactly one nucleotide in front of the SNP locus.
- This primer can be extended by the DNA polymerase by incorporating dideoxynucleotide triphosphates (ddATP, ddTTP, ddGTP and ddCTP), which leads to a strand termination immediately after the incorporation of one of these bases.
- ddATP, ddTTP, ddGTP and ddCTP dideoxynucleotide triphosphates
- An individual color marking of the four dideoxynucleotides can now be used to determine which base has been incorporated or which of the corresponding complementary bases is present on the sample molecule.
- oligonucleotide ligation assay Two oligos are tailored in such a way that they hybridize directly next to each other at the SNP site with the sample molecule. The 5 'end of the first oligo is provided with a phosphate and the 3' end of the other oligo Wundt. If there is a perfect match, the oligos are now connected by the DNA ligase. This reaction does not occur in the event of a mismatch. The identity of the base at the SNP position can finally be deduced from the detection of the ligation product.
- the object of the present invention was to provide a method with which mutations, in particular polymorphisms, can be detected without the need for complex separation steps, such as electrophoresis. Furthermore, it was an object of the invention to provide a method which offers the possibility of parallelizing tests.
- a method for the detection of mutations in a ' nucleic acid which comprises that a) a plurality of strands of nucleic acid to be analyzed are brought into contact with at least two types of oligonucleotides, receptor oligos and probe oligos, under such conditions that the Oligos hybridize with the DNA to be analyzed to form a sample complex and a reference complex, so that there is a chain of sample complex and reference complex immobilized or immobilizable on both sides, b) the chain is subsequently immobilized if necessary, c) a tensile force is applied to the chain until it pulls one of the complexes is separated and d) it is determined which of the complexes has been separated.
- the analyte nucleic acid is brought into contact with two types of oligonucleotides, receptor oligos and probe oligos, under conditions such that the oligos hybridize with the analyte nucleic acid, the oligonucleotides being immobilized or immobilizable, and where appropriate, the oligonucleotides are immobilized after the hybridization, so that a mutually immobilized or immobilizable chain of receptor oligo - analyte nucleic acid - probe oligo is present; a tensile force is applied to the linkage so that one of the bonds is released and it is determined which of the bonds has been released, the receptor oligonucleotides having a sequence which is essentially complementary to a sequence section of the analyte nucleic acid in which a mutation or Variation is suspected.
- the principle of the differential force test is used for the method of the present invention.
- the general principle of the differential force test is described in PCT / EP01 / 09206. It has been found that the use of the differential force test allows the detection of polymorphisms reliably and to a large extent in parallel and in a miniaturized manner, whereby point mutations (SNP) as well as other changes in the sample sequence can be detected, provided that they lead to a change in the separating force of the duplex formed when hybridizing with the strand complementary to the Wiid type.
- SNP point mutations
- a nucleic acid molecule in a sample which is also referred to below as analyte nucleic acid
- a sample complex is formed from a first and a second binding partner.
- One of the two binding partners - the analyte nucleic acid - contains a defined sequence section (sample sequence) of an analyte molecule.
- the other of the two binding partners contains a defined sequence section (receptor sequence) of a receptor oligo, which is essentially complementary to the section of the analyte sequence of interest.
- the hybridization of the first binding partner with the second binding partner leads to the formation of a sample complex.
- a third and a fourth binding partner together form a reference complex.
- Sample complex and reference complex are linked together in series.
- Two of the participating binding partners are immobilized or immobilizable so that a tensile force can be exerted after the reaction to the chain formed.
- a tensile force is applied to the ends of the chain until one of the two complexes is separated, namely either the first from the second binding partner, ie the sample complex, or the third from the fourth binding partner, ie the reference complex.
- the sample complex is dissolved if its separating force under the test conditions is less than that of the reference complex
- the reference complex is dissolved if its separating force is less than that of the sample complex under the test conditions.
- the discrimination of mutations compared to the wild type by a force comparison is based on the fact that the ratio F * Re f / F * Pra also changes due to the change in F * Pr o.
- the reference complex is usually also a nucleic acid duplex, the fourth binding partner corresponding to the probe sequence and being called probe oligo.
- Binding partner 3 is essentially complementary to or corresponds to the reference sequence and is preferably part of the sample molecule to be analyzed.
- the method according to the invention is described for determining a mutation, but it can also be used for determining variations in a nucleic acid. Therefore, when the term “mutations" is used below, variations should also be included.
- an analyte nucleic acid on which mutations are to be detected, is brought into contact with different oligonucleotides in such a way that at least two nucleic acid duplexes are formed which are linked to one another in such a way that a chain is formed on the two ends of which force can be exerted. Furthermore, this linkage is designed such that, when a force is exerted on this linkage, one of the two hybridized duplexes or complexes separates, depending on which duplex or complex has the lower binding force under the given conditions. In the case of nucleic acid strands which are not hybridized in the Unzip mode, this depends primarily on the number of paired bases, the type of bases, in particular the GC content, and the number of mismatches.
- the essence of the invention is that the binding force of two duplexes is compared with one another, the analyte nucleic acid being involved in at least one of the two duplexes.
- the chain In order to be able to exert a force on the chain formed by hybridization of the individual partners, the chain must be immobilized on both sides on a carrier. Therefore strands are used for the duplexes, which are either already immobilized or immobilizable.
- immobilized nucleotides are already used for the hybridization, while in other embodiments the hybridizations are carried out first with mobile nucleotides and the immobilization takes place in a subsequent step. In the latter case, a binding possibility must of course be provided for the immobilization on the strands to be immobilized.
- stamp and base
- base the term “stamp” and base” will be used, without the intention to determine the spatial position, nature or function, since the stamp can also serve as a base and vice versa.
- immobilization on beads or particles takes place instead of macroscopic surfaces.
- receptor and probe oligonucleotides must be immobilized or immobilizable.
- the three components are brought into contact with one another in such a way that they can hybridize with one another.
- the receptor oligo can be immobilized in a manner known per se on a surface mentioned for the sake of simplicity, for example by covalent bonding via functional groups located on the support.
- the immobilization should take place in such a way that a duplex is formed in the hybridization, which is not zipped open when a tensile force is applied.
- the pad with the bound receptor oligos is then brought into contact with the analyte nucleic acid so that hybridization can take place, a sample complex being formed.
- the probe oligonucleotide can then either simultaneously with the analyte nucleic acid or subsequently added or immobilized on a second surface called a stamp and then brought into contact with the nucleic acids bound on the support in such a way that hybridization occurs between probe oligo and analyte nucleic acid, a reference complex being formed. In this way, a chain can be formed, which consists of immobilized reference oligo, analyte nucleic acid and immobilized probe oligo.
- a tensile force can be exerted on this concatenation via the surfaces or supports on which the oligonucleotides are immobilized.
- the weaker of the two bonds breaks, ie either the bond between receptor oligo and analyte nucleic acid or between probe oligo and nucleic acid.
- the sequence is only described here as an example. Other sequences of chaining are also possible. It is then proven which of the two bonds has broken.
- a receptor oligonucleotide is immobilized and brought into contact with the sample which contains the nucleic acid to be analyzed, so that the analyte nucleic acid can hybridize with the receptor oligo, the sequence of the working steps being arbitrary.
- a stamp is prepared on which the probe oligonucleotide is immobilized.
- a reference nucleotide is hybridized with this probe oligonucleotide, which has a base sequence which is outside of the range in which mutations are suspected to a sequence of the analyte nucleic acid.
- the order of the work steps is arbitrary.
- the number of base pairs hybridizing with one another between this reference strand and the analyte nucleic acid is far higher than that of the reference complex and sample complex to be formed and only serves to reliably connect the two complexes to be checked.
- This additional hybridization strand should definitely be as many
- the analyte nucleic acid is immobilized on a base.
- the base with immobilized analyte nucleic acid is brought into contact with the receptor oligonucleotide under conditions such that hybridization can take place.
- a probe oligonucleotide is immobilized on a stamp and hybridized with a reference strand, as explained in the previous variant. Both the receptor oligonucleotide and the reference strand have mutually complementary bases. The base and stamp are then brought into contact with one another in such a way that the complementary bases of the reference strand and receptor oligonucleotide can hybridize with one another.
- the number of base pairs hybridizing with one another between this reference strand and the receptor oligonucleotide is far higher than that of the reference complex and sample complex to be formed and only serves to reliably connect the two complexes to be checked.
- This additional hybridization strand should in any case have so many base pairs that bind to one another that its separating force is far above the separating force of the two complexes, so that it remains in any case.
- a tensile force is then again exerted on the linkage formed from analyte nucleic acid, receptor oligonucleotide, reference strand, probe oligonucleotide, which in turn releases the bond which has the lowest separating force.
- a nucleic acid to be examined is brought into contact with two different oligonucleotides, of which one oligonucleotide has a defined sequence section which is complementary to the region of the nucleic acid to be analyzed in which the variation or mutation is suspected.
- This oligonucleotide is called receptor oligo.
- the second type of oligonucleotide, with which the nucleic acid to be analyzed is brought into contact with has a defined sequence section which is complementary to another section.
- This oligonucleotide is called probe oligo.
- the sequence of the probe oligo should not hybridize to the same section as the receptor oligo to avoid cross reactions.
- the single strands should not interfere with each other in the hybridization.
- the probe oligo can have the reverse sequence to the sequence of the receptor oligo. This has several advantages. It simplifies the production of the oligonucleotides, prevents cross reactions and creates complexes that are comparable in terms of binding power.
- At least one of the nucleic acids used has a label.
- Two of the nucleic acids used are preferably provided with a label.
- the label can be inherent to the molecules or duplexes or can be introduced.
- the nucleic acid to be analyzed is provided with a label.
- the type of labeling depends, among other things, on how the nucleic acid to be examined was obtained. In this way, the label can be bound directly to the nucleic acid to be examined.
- the labeling is introduced by generating the nucleic acid to be examined using PCR, the primer to be used for this purpose having a label, the pair of primers used for the PCR having a sequence which flanks the site, which contains the possible variation, or wherein the incorporated nucleotides have a label.
- any analytically detectable group or substance can be used as a marker for the method according to the invention.
- labeling is understood to mean a property by which some binding partners differ from others and which is detectable. Physically detectable parameters are preferably used.
- the label may be inherent to the molecule or complex, or may be introduced or bound.
- radioactive atoms or groups that change the optical or electrical effect properties.
- All reporter groups known to the person skilled in the art are suitable here. Examples are radioactive markers such as 3 H, 14 C, 32 P, 35 S, fluorescent, luminescent, chromophoric groups or dyes, semiconductor particles, metals or conductive groups, but also substrates of enzymes or reporter enzymes. Fluorescent or chromophoric groups are preferably used as the label. At least one of the oligonucleotides has a label.
- the label is preferably a fluorescent dye, for example fluorescein isothiocyanate (FITC), fluorescein, rhodamine, tetramethylrhodamine 5- (and-6) -isothiocyanate (TRITC), Texas Red, cyanine dyes (CY3 or CY5) etc. fluorescent dyes are advantageous because they can be detected in very small amounts.
- fluorescent dyes for example fluorescein isothiocyanate (FITC), fluorescein, rhodamine, tetramethylrhodamine 5- (and-6) -isothiocyanate (TRITC), Texas Red, cyanine dyes (CY3 or CY5) etc.
- fluorescent dyes are advantageous because they can be detected in very small amounts.
- two markings are used per chain, which are preferably different from one another.
- different fluorescent markings those can be used which are each excited by light of the same wavelength or by radiation of different wavelengths.
- the marking serves to demonstrate where the probe oligo or reference oligo is located and, where appropriate, where the receptor oligonucleotide or the analyte which can be hybridized with the analyte nucleic acid is after applying a tensile force (examples can be found in FIG. 4). This information can then be used to derive which strands have connected and separated from one another. From this it can be concluded whether the analyte nucleic acid shows variations or mutations compared to the wild type.
- the double marking ensures that only those chains that were linked are evaluated.
- the nucleic acid to be examined can be genomic DNA, RNA, PNA or modifications. It can also be c-DNA.
- the nucleic acid can be obtained directly from cells and, if enough copies of the sequence are present in the cell, this sequence can be used directly for the test.
- the nucleic acid to be examined is amplified in a first step with a PCR and the amplified product is then used for the method according to the invention.
- the amplification is preferably carried out with a labeled primer in order to obtain labeled nucleic acid sequences in this way.
- the primers are selected in a manner known per se so that they flank the sequence of interest.
- the primers can each have a length of up to 30 nucleotides, preferably 15 to 20 nucleotides.
- the length of the nucleic acid used depends, among other things, on whether a mutation or variation or several variations or mutations are to be detected and in which region these are then located.
- the method according to the invention is particularly well suited for nucleic acid sequences with up to 100 nucleotides, in particular for those sequences which have 30 to 50 nucleotides. Even shorter nucleic acid sequences can be used to detect known single base mutations.
- the labeled nucleic acid to be analyzed is brought into contact with a receptor oligo and a probe oligo.
- the receptor oligo is a nucleic acid that is complementary to one end of the nucleic acid to be analyzed, while the probe oligo is complementary to the other end or a reference strand.
- the receptor oligo has a nucleotide sequence that either corresponds to the section of interest of the wild-type sequence of the nucleic acid to be examined, or has a variation or mutation.
- the sequence corresponding to the wild-type nucleic acid is referred to as receptor w ⁇ - oligos, while those receptor oligos which contain variations and mutations are referred to as receptor M- oligos.
- the mutations and variations can be the exchange of one or more bases, preferably a base, or the change of one or more bases, which leads to a change in the binding behavior. Any conceivable change in the chemical structure of the nucleotide is understood as a mutation or variation, which causes a separation force difference in a force comparison compared to an original state.
- the probe oligo is used to form a reference complex with another strand, which can be the analyte nucleic acid or a reference strand.
- the reference complex should be as similar as possible to the test complex in order to enable the differentiation of small separation force differences between two test complexes.
- a nucleotide sequence which is complementary to a part of the nucleic acid to be analyzed and in which no mutation or variation is suspected is preferably used as the probe oligo.
- the sequence of the probe oligo is preferably selected such that a perfect match occurs here when hybridizing with the reference strand or the reference sequence.
- the length of the hybridizing sequence of the probe oligo is preferably selected so that the force necessary to separate the reference complex is very close to the force necessary to separate the sample complex. If a sequence is selected for the reference complex that has the same GC ratio as the sample complex, the number of base pairs is preferably in the same range and preferably differs only by up to 2 base pairs. If the GC ratio differs between the two complexes, the length of the sequence to be hybridized can be selected so that the separation force approaches that of the sample complex. The insertion of one or more mismatches can also be used to set the optimal reference complex.
- the nucleic acid to be analyzed is contacted with receptor oligos and probe oligos under conditions such that hybridization can take place.
- the probe oligo hybridizes with one end of the DNA to be analyzed to form a perfect match, while the other end of the DNA to be examined hybridizes with receptor oligos, resulting in a perfect match or a mismatch, depending on whether the sequence of the receptor corresponds to corresponds to investigating DNA or not.
- oligonucleotides or the analyte are therefore either already used in immobilized form or else immobilizable oligonucleotides or analytes are used which are immobilized after the hybridization.
- Immobilization of the oligonucleotides can be carried out in a manner known per se by binding the nucleotides to a support or a surface via spacers or bridge molecules.
- the support or the surface must be designed so that a tensile force can be applied.
- These can be macroscopic surfaces, but also other solid bodies, such as beads, or molecules.
- the immobilization takes place particularly preferably in that the receptor oligonucleotides are or are immobilized on a first surface, while the probe oligos are immobilized or are immobilized on a second surface.
- the material from which the surfaces are made can be the same or different and one or both surfaces can be coated in a suitable manner.
- either one surface is made of a rigid material and the other is made of an elastic material, or both surfaces are made of elastic material, so that the respective surface sections of the first and second surfaces are accurate when brought into contact can adapt to each other and thus an optimal contact of the individual nucleic acid ranks and possibly binding partners is possible.
- the surfaces can be formed, for example, from glass, silicone, in particular polydimethylsiloxane (PDMS), nylon, polystyrene or other plastics. At least one of the two surfaces is preferably produced from an elastic material, preferably an elastic plastic.
- At least one surface is particularly preferably formed from a siloxane, in particular polydimethylsiloxane.
- a siloxane in particular polydimethylsiloxane.
- Various other flexible materials or mixtures thereof are possible.
- Another possible material is polyacrylamide gel, the elastic properties of which can be adapted to experimental requirements through the molecular weight and the degree of crosslinking.
- the surface can be constructed from a single material, a mixture of materials or also a system of elements from one or different materials.
- the immobilization of the oligonucleotides or nucleic acids can be carried out in a manner known per se, both covalent and non-covending bonds and bonds directly to the surface or via bridging molecules can be considered. Immobilization via the partners of a specifically binding couple is also possible. The immobilization should take place in such a way that a duplex is formed in the hybridization, which is not separated like a zipper when a tensile force is applied.
- one of the two partners of the specific binding pair is permanently immobilized and the other is bound to a nucleotide or the analyte nucleic acid, whereby permanent binding is understood here to mean a bond which remains essentially stable before the surfaces are brought into contact and which is also bonded of the attachment partner to its specific counterpart.
- a permanent bond can e.g. via functional groups which the binding partner has or which have been introduced into the molecule, to functional groups which are provided by the surface.
- a preferred method is to biotinylate a partner and to connect it to the likewise biotinylated surface via a streptavidin molecule.
- Monoclonal antibodies can be activated chemically by oxidizing certain groups of their glycosylations to aldehyde groups. These aldehyde groups can in turn Bind amino groups or hydrazide groups of a modified surface (see Solomon et al., Journal of Chromatographie, 1990, Vol. 510, 321-329).
- Another method which is known to the person skilled in the art is the conjugation of amino groups of the antibody with carboxy groups of a surface by using ethyl (dimethylamino) carbodiimide / N-hydroxy-succinimide.
- the immobilization of the oligonucleotides can be carried out in a manner known per se via spacers or bridge molecules.
- the person skilled in the art knows possibilities with which nucleotides can be bound to surfaces.
- the immobilization should take place in such a way that the sequence complementary to the nucleic acid to be analyzed is accessible for hybridization.
- oligonucleotides are used which can be immobilized and are only immobilized after the hybridization.
- both only one type of oligonucleotide and both types of nucleotides can be immobilized.
- the immobilizable nucleotides used are those which have a partner of a specific binding pair at one end, the other partner of the specific binding pair being covalently bound to a surface. When the nucleotides are brought into contact with the surface, the specific binding partners are bound, which results in immobilization.
- a wide variety of mutually bindable partners can be considered as specifically bindable pairs, the specificity of the bond being able to relate both to a specific partner, e.g. Antigen-related antibody or biotin-avidin / streptavidin, as well as on a group or class of compounds, e.g. Antibody protein A.
- antibodies and a substance with an epitope recognized by it are used as the binding pair.
- the term “antibody” also includes antibody fragments or antibody derivatives, as well as functional fragments of Antibodies or derivatives thereof that can recognize and bind the epitope are understood.
- the antibodies can be polyclonal or monoclonal antibodies, but monoclonal antibodies are preferred.
- Known fragments and derivatives are Fv, Fab, Fab 'or F (ab') 2 fragments, "single-chain antibody fragments", bispecific antibodies, chimeric antibodies, humanized antibodies and fragments that contain CDRs (complementarity determining regions). contain an epitope of the sample.
- the selection of the specifically binding pair is not critical. It is only important that the separation force required to separate the specifically binding pair is greater than the separation force required to separate the hybridized strands.
- the DNA to be analyzed is reacted with receptor oligonucleotide and probe oligonucleotide under conditions which permit hybridization and then immobilization by bringing the hybridized molecules into contact with two surfaces, each of which provides specifically binding partners for the two oligonucleotides brought about.
- one of the two oligonucleotides is immobilized on a surface, then brought into contact with the other type of oligonucleotide and the nucleic acid to be analyzed so that it binds to receptor oligonucleotide - analyte nucleic acid - probe oligonucleotide one surface, and then the second surface is brought into contact with this concatenation so that a binding partner of a specific binding pair bound to the second surface can bind to the nucleotide which has not yet been immobilized and provided with a binding partner.
- receptor oligonucleotides are immobilized on a first surface, while probe oligonucleotides are immobilized on one second surface can be immobilized. Either the first surface or the second surface is then brought into contact with the analyte nucleic acid under conditions such that hybridization takes place and then the other surface is brought into contact with the analyte nucleic acid now bound to an oligonucleotide so that further hybridization can take place. so that a chain is formed again.
- probe oligonucleotide with analyte nucleic acid is usually a perfect match, this is the case if there is at least one mismatch in the hybridization between receptor oligonucleotide and the DNA to be analyzed or if a nucleotide is changed so that the binding is weaker than a "normal" nucleotide.
- probe oligonucleotide for any desired analyte nucleic acid
- four different receptor oligos can be used for the detection of an SNP, for example, which differ in the base at the location suspected for the SNP, so that each base occurs once at this location. If the process according to the invention is then carried out simultaneously with the four receptor oligos and the frequency with which complexes with receptor oligos have separated is compared, it can be expected that the result for the three oligos in which a mismatch is to be expected differs from the one oligo that created a perfect match. This embodiment therefore leads to particularly meaningful results.
- a method is thus made available with which mutations or variations of a nucleic acid sequence can be detected simply and quickly.
- the essence of the invention is that many hybridizations can be carried out at the same time and the separating force of the hybridized strands on many molecules can be demonstrated simultaneously.
- the method becomes even more meaningful by using a second marking.
- both the nucleic acid to be analyzed is labeled and the probe oligonucleotides.
- the probe oligonucleotides can be immobilized, but are not yet immobilized in the reaction with the DNA to be detected.
- the probe oligonucleotides are provided with a label which differs from the label with which the DNA to be analyzed is provided.
- analyte nucleic acid is again brought into contact with receptor oligonucleotides and probe oligonucleotides
- hybridization and then immobilization is brought about and then a tensile force is applied to the chaining on both sides in order to bind one of the To solve chaining.
- a surface is then analyzed to determine how much of the probe oligonucleotide has bound to the surface and how much of the DNA to be analyzed has bound.
- the sequence of the work steps is variable. However, it should be ensured that the unlabeled components are immobilized first and the marked ones last.
- the method according to the invention has various advantages over the methods of the prior art. It has the advantage over the known enzymatic methods that no enzymes have to be used, which saves costs. In addition, when carrying out the process and selecting the reactants, e.g. the enzymes are not taken into account in the composition of the buffer.
- heteroduplexes for which no enzymes are available can also be used, e.g. for DNA-RNA or DNA-PNA duplexes.
- SSP single-stranded DNA sequence
- many samples can be tested in parallel without a cross reaction, as is the case with many primer pairs in the same approach.
- FIG. 1 shows the principle of the method according to the invention, a force being exerted on a chain of receptor oligonucleotide analyte nucleic acid and probe oligonucleotide which is immobilized on both sides. The two options for separating the complex are shown.
- Figure 2 shows two examples of the concatenation of a wild type receptor with analyte nucleic acid and probe oligonucleotide and a mutant receptor with analyte nucleic acid and probe oligonucleotide.
- 3 shows the different possibilities for coupling the components receptor oligonucleotide, analyte nucleic acid and probe oligonucleotide.
- FIG. 5 shows the fluorescence scan of a spot which was transferred to a stamp (Example 2)
- FIG. 6 shows the ratio of the fluorescence intensities for two spots transferred to the stamp. Mismatch (left) and Perfect Match (right). (Ex. 3)
- FIG. 7 shows a histogram of the ratios of the fluorescence intensities for mismatch spots and perfect match spots (Ex. 3).
- FIG. 8 shows the hybridization scheme of the oligonucleotides used in Example 4.
- FIG. 9 shows the transfer of a PM spot and an MM spot to the stamp in the embodiment of example 4 above; below, PM and MM spots are shown on the slide after stamping; the respective histograms can also be seen. The following five variants are shown in FIG.
- the receptor oligonucleotide is immobilized on a support. It hybridizes with the analyte nucleic acid. At its other end, the analyte nucleic acid has a specifically bindable grouping which is reacted with the corresponding binding partner.
- the binding partner has a binding site that can bind to a stamp. Through the coupling step, the binding partner is immobilized on the stamp, so that a chain is formed on which a tensile force can be exerted.
- a binding partner is immobilized on a surface and reacted with the specifically binding partner that is present on an analyte nucleic acid.
- the analyte nucleic acid immobilized on the surface via the specific binding pair is brought into contact with a receptor oligonucleotide which has at its other end a group which can bind to a surface. Binding of the receptor oligonucleotide to the surface in turn creates a chain on which a tensile force can be exerted.
- an analyte nucleic acid is bound via a specifically binding pair.
- a receptor oligonucleotide is immobilized on a second surface. Both surfaces are then brought into contact so that the complementary nucleotides of receptor oligonucleotide and analyte nucleic acid can hybridize. A force can then be exerted on the chain formed.
- a receptor oligonucleotide is immobilized on a surface and brought into contact with an analyte nucleic acid in such a way that hybridization can take place.
- the analyte nucleic acid has a partner of a specific binding pair at its other end.
- the other partner of this specific binding pair is immobilized on a second surface.
- the two surfaces are then brought into contact with one another in such a way that the specifically binding pair is bound. This creates a chain again, on which a force can then be exerted.
- a receptor oligonucleotide is immobilized on a surface and is brought into contact with the analyte nucleic acid so that complementary nucleotides can hybridize with one another.
- a specific binding pair is immobilized on a second surface. Both the non-immobilized second partner of the specific binding pair and the analyte nucleic acid each have a binding site that can react with one another. When these two groups have reacted with each other, a chaining occurs again, on which tension can be exerted.
- the two partners of the specifically binding pair are two complementary nucleic acid strands which form a reference complex.
- the nucleic acid strands are provided in such a way that they differ in a predetermined manner from the sample complex in terms of the free base pairing energy and the number of mismatches or, if appropriate, are identical in terms of the free base pairing energy and number of mismatches.
- the sample and reference complex are particularly preferably selected such that the free base pairing energy ⁇ G differs as little as possible. A reliable determination is no longer possible if the free base pairing energy of the sample complex and reference complex differs by more than 40 kcal / mol.
- the free base pairing energy of the sample and reference complex preferably differs by no more than 20 kcal / mol. Particularly good results are obtained if the difference between the sample and reference complex is ⁇ 4 kcal / mol.
- Samples to determine the free base pairing energy of nucleic acid duplexes are known. One method is described, for example, in KJ Breslauer, R. Frank, H. Blöcker and LA Markie "Predicting DNA Duplexes Stability From The Base Sequence", Proc. Natl. Acad. Be. USA, vol. 83, pages 3746-3750, 1986.
- Receptor oligo Oligo, which forms a sample complex with the analyte.
- Probe oligo Oligo, which forms a reference complex with the analyte or the reference strand
- Analyte oligo, PCR product or other nucleic acids on which a polymorphism or a mutation is to be detected.
- Sample mixture substance mixture that contains the analyte
- Binding partner partner of a specific binding pair wild type: original, or mutant form of the sample sequence mutation: changed or wild type of the sample sequence, which leads to a change in the separating force of the sample complex
- the following embodiment is the detection of a possible single base variation (G ⁇ C) at a known base position on genomic DNA.
- An amplicon of genomic DNA is produced by PCR (sample molecule corresponds to analyte nucleic acid).
- the pair of primers flanked a sequence of 30 base pairs, which identified the site with the possible base exchange contains.
- Primer 1 which hybridizes to the non-codogenic strand of the genomic DNA and is extended to copy the codogenic strand, is labeled with a Cy3 molecule.
- Approx. 100 femtoMol of one of two different receptor oligos are bound on two separate spots of 1 mm 2 each on a slide coated with covalently bound streptavidin.
- the free streptavidin surface of the coating surrounding the spots is saturated with a biotinylated poly-A-oligo of 15 bp length.
- the wild-type receptor (Rez W ⁇ ) is a 28 nucleotide-long DNA oligo that is modified at the 5 'end with biotin, whereby it is bound to the streptavidin surface.
- Bases 1-10 serve as poly-A spacers.
- Bases 11-28 (all bases counted in the 5'-3 'direction) represent the receptor sequence of Rez W ⁇ . This section of the sequence is complementary to bases 30 to 48 of the amplified codogenic strand of the genomic DNA in the non-mutated form ,
- the mutant receptor (Rez M ) is a 28 nucleotide long oligo which is modified at the 5 'end with biotin, with which it is bound to the streptavidin surface.
- Bases 1-10 serve as poly-A spacers.
- Bases 11-28 represent the receptor sequence of Rez M. This sequence section is complementary to bases 30 to 48 of the codogenic strand of the mutant form of genomic DNA, which differs from the non-mutated form at base 19, in which a C against a G is exchanged.
- Rez M is therefore completely complementary to a mutant DNA in which a G is replaced by a C at base 39.
- the sample with the Cy3-labeled sample molecules, which are a copy of the codogenic strand, is denatured by boiling and prevented from re-hybridizing by cooling on ice.
- the probe oligo (probe) is added to the sample mixture. This is a 28-bp DNA oligo.
- the probe is at its 5 'end with a Cy5 molecule and labeled at its 3 'end with a biotin.
- Bases 1-18 represent the probe sequence and are complementary to bases 18-1 of the sample molecule, which represent the reference sequence.
- the probe-added sample is then placed in 5 x SSC buffer for hybridization on the receptor spots of the blocked slide. After an incubation of 30 min at RT, the mixture is washed with 1 x SSC and covered with 1 x SSC.
- the hybridization leads to the formation of the sample complex and the reference complex, as shown in FIG. 2, the concatenation being linked to the slide via the receptor.
- a microstructured PDMS stamp coated with streptavidin is now pressed onto the area of the receptor spots with the immobilized chains under 10OmM NaCl buffer. This involves connecting the biotinylated probe oligos to the stamp or coupling the linkages between the stamp and the slide. The stamp is separated from the specimen slide after 30 minutes, the linkages being separated by separating one complex at a time. It should be noted that this process is carried out simultaneously on very many (-100 fMol) chains on each spot.
- the stamp is now evaluated in a fluorescence scanner with regard to the markers Cy3 and Cy5.
- the probe oligos and sample molecules transferred to the stamp can thus be quantified.
- the amount of Cy5 transferred from the spots to a specific area of the stamp is related to the amount Cy3 transferred to the same area.
- the quotients obtained for the two spots are compared with one another.
- the sample molecule is in wild-type form (no exchange from G to C at base 39).
- the separation force for the sample complex from Rez W ⁇ is therefore greater than the separation force for the sample complex from Rez M :
- the sample molecule is in the mutant form (G was exchanged for C at base 39).
- the separation force for the sample complex of Rez W ⁇ is smaller than the separation force for the sample complex of Rez M : F * Pra (Rez W ⁇ ) ⁇ F * Pra (Rez M )
- sample molecules were oligonucleotides which were built up from 5 'to 3' from the following sequence components:
- a reference sequence of 16 or 14 nucleotides, an internal spacer sequence of 16 or 20 nucleotides, a sample sequence with 16 or 14 nucleotides and a terminal spacer sequence of 4 nucleotides were reversed to each other.
- the receptors consisted of an amino-C12 linker conjugated at the 5 ' end, a spacer of 10 nucleotides without specific binding function (here 10x adenine) and a selected receptor sequence with a length of 16 or 14 nucleotides.
- receptors with a base exchange were put together.
- the cytosine at position 7 was replaced by adenine.
- cytosine at position 12 was replaced by adenine.
- the probe oligos consisted of a Cy5 molecule conjugated at the 5 ' end, a spacer of 4 nucleotides with no specific binding function (4x adenine) and a sequence that was complementary to the reference sequence (16 or 14 nucleotides), as well as a further spacer ( 10x adenine) with a 3'-terminal biotin group.
- the structure of the chains of the 16-mer sample molecule :
- 0.5 ⁇ l of a 10 ⁇ M oligo solution was spotted in 0.1 M NaCl on a slide coated with epoxysilane and incubated overnight in a moist chamber. Then 2 x 5 minutes in 1 x SSC-T (T is addition of 0.05% Tween-20) and 2 x 2 minutes in dist. Washed water and dried with a stream of nitrogen.
- the spots of the wild-type and mutant receptors were incubated for 30 minutes with a mixture of Cy3-labeled sample molecule and Cy5-labeled probe oligo in a concentration of 0.5 ⁇ M in 5xSSC, 0.05% Tween-20.
- the hybridization led to the formation of the sample complex and the reference complex, as shown above, the chain being linked to the slide via the receptor.
- the slides were 2 x 2 minutes with 5 x SSC-T, 2 x 2 minutes with 1 x SSC-T and 2 x 2 minutes with 0.2 x SSC-T, briefly watered and dried in a stream of nitrogen.
- a micro-structured stamp was made from PDMS (polydimethylsiloxane).
- the structures consisted of stamp feet of approx. 100 x 100 ⁇ m, which were separated by depressions approx. 25 ⁇ m wide and 1 ⁇ m deep.
- a mixture of a 1:10 mixture of crosslinking reagent and silicone elastomer (Sylgard 184, Dow Corning) was poured onto a correspondingly structured silicon wafer after multiple degassing and incubated for 24 hours at RT. After the polymerization, the structured surface of the stamp was exposed to H 2 O plasma at 1 mbar in a plasma furnace for 60 s.
- the oxidized surface was incubated with 3% aminosilane (3-aminopropyldimethylethoxysilane; ABCR, Düsseldorf) in 10% H 2 O and 87% ethanol for 30 min.
- the silanized surface was washed with ultrapure water and blown dry with nitrogen.
- a bifunctional PEG was attached to the amino groups of the silane, one end of which had a carboxy group activated by NHS and the other end had a biotin group.
- 20 ⁇ l of a solution with 2 mg / 100 ⁇ l of NHS-PEG-Biotin (Shearwater, Huntsville) were incubated under a cover glass for 1 h on a stamp with an area of 1 cm 2 .
- the stamp was measured in a fluorescence scanner (Axon, Genepix 4000 B) with a spatial resolution of 5 ⁇ m with regard to the intensities of Cy3 (excitation at 532 nm) and Cy5 (excitation at 635 nm).
- the fluorescence scan of a spot that was transferred to the stamp is shown in FIG. 5.
- FIG. 5 shows a typical histogram of a spot for one of the two markings.
- the histograms have two distinct maxima. The maximum at low intensity corresponds to the fluorescence background (dark grid), that at higher intensity corresponds to the actual signal (light areas).
- the sample molecule was an oligonucleotide that was built up from 5 'to 3' from the following sequence components:
- the receptors consisted of a biotin group conjugated at the 5 ' end, a spacer of 10 adenines and a selected receptor sequence with a length of 16 nucleotides. Matching the wild-type receptor sequence with a length of 16 nucleotides, a mutated receptor with a base exchange was derived, in which cytosine at position 12 was replaced by adenine.
- the probe oligo consisted of a Cy5 molecule conjugated at the 5 ' end, a spacer consisting of 4 adenines and a sequence with 16 nucleotides, which is complementary to the reference sequence, and a further spacer composed of ten adenines with a 3'-terminal biotin group.
- the slide was covered with a 2 ⁇ M solution of a biotinylated DNA oligo (in 1x SSC, 1% Tween) and incubated for 15 min. It was Washed 2 x 10 min with 1 x SSC-T (T is addition of 0.05% Tween-20) and the remaining drops were removed with a stream of nitrogen (not dried).
- a biotinylated DNA oligo in 1x SSC, 1% Tween
- the spots of the wild-type and mutant receptors were incubated for 30 minutes with a mixture of Cy3-labeled sample molecule (0.25 ⁇ M) and Cy5-labeled probe oligo (1 ⁇ M) in 5xSSC.
- a micro-structured stamp was made from PDMS (polydimethylsiloxane).
- the structures consisted of stamp feet of approx. 100 x 100 ⁇ m, which were separated by depressions approx. 25 ⁇ m wide and 1 ⁇ m deep.
- a mixture of a 10: 1 mixture of silicone elastomer (Sylgard 184, Dow Corning) and crosslinking reagent was poured onto a correspondingly structured silicon wafer after repeated degassing and incubated for 24 hours at RT. After the polymerization, the structured surface of the stamp was exposed to H2O plasma at 1 mbar in a plasma oven for 60s.
- the oxidized surface was incubated with 3% aminosilane (3-aminopropyldimethylethoxysilane; ABCR, Düsseldorf) in 10% H2O and 87% ethanol for 30 minutes.
- the silanized surface was washed with ultrapure water and blown dry with nitrogen.
- a bifunctional PEG was attached to the amino groups of the silane, one end of which had a carboxy group activated by NHS and the other end had a biotin group.
- 20 ⁇ l of a solution with 2 mg / 100 ⁇ l of NHS-PEG-Biotin (Shearwater Polymers, AL) were incubated under a cover glass for 1 h on a stamp with an area of 1 cm 2 biert.
- a freshly prepared stamp and a base were pressed onto the spots with a solution of 30 mM NaCl under a pressure of 100 g / cm 2 .
- the stamp was lifted off after 30 minutes. Slides and stamps were washed with ultrapure water and blown dry with nitrogen.
- the stamp was measured in a fluorescence scanner (Axon, Genepix 4000 B) with a spatial resolution of 5 ⁇ m with regard to the intensities of Cy3 (excitation at 532 nm) and Cy5 (excitation at 635 nm).
- a fluorescence background was determined and subtracted for both measurement images.
- the measurement images adjusted for the background were processed further by determining the quotient of the fluorescence intensities (635nm / 532nm) for each pixel. As a result, a quotient image of the fluorescence intensities was obtained, as shown in Figure 6 for two spots.
- the low peaks in the histogram corresponded to the stamp areas (dark rectangles in FIG. 6), the high peaks to the depressions in the stamp, to which no fluorophores were transferred (light grid in FIG. 6).
- the mean intensity quotients V maximum of the low peaks
- VM mutant
- VPM wild type
- VMM mutant
- VPM wild type
- VMM VPM ⁇ 1
- a sample sequence of 20 nucleotides in length should be checked for a possible exchange of a single guanine for a cytosine.
- the Pfob molecule (analyte) was an oligonucleotide with a Cy5 molecule conjugated at the 5 ' end, which was constructed from 5' to 3 'from the following sequence components:
- a reference sequence of 20 nucleotides, an internal spacer sequence of 11 nucleotides, a sample sequence of 20 nucleotides and a terminal spacer sequence of 5 nucleotides (here 5 x adenine). Sample sequence and reference sequence were reversed to each other.
- the receptors consisted of an amino-C6 linker conjugated at the 5 ' end, a spacer of 10 nucleotides without specific binding function (here 10x adenine) and a selected receptor sequence with a length of 20 nucleotides. Matched to the wild-type receptor sequence (receptor PM) with a length of 20 nucleotides derived a mutated receptor (receptor MM) with a base exchange in which guanine at position 13 was replaced by cytosine.
- receptor PM wild-type receptor sequence
- receptor MM mutated receptor
- the probe oligo consisted (in 5 ' -> 3 ' direction) of a spacer of 5 nucleotides (here 5x adenine) without a specific binding function and of a sequence that was complementary to the reference sequence (20 nucleotides), as well as a further spacer (10xAdenine) a 3'-terminal biotin group.
- Figure 8 shows the hybridization scheme of the oligonucleotides used.
- the spots of the wild-type and mutant receptors were incubated for 1 hour with a mixture of Cy5-labeled sample molecule and unlabeled probe oligo in a concentration of 0.1 ⁇ M in 5xSSC.
- the hybridization led to the formation of the sample complex and the reference complex, as shown above, the chain being linked to the slide via the receptor.
- the slides were washed for 10 minutes with SSC / 0.1% SDS or 1xSSC minutes and briefly blown dry in a stream of nitrogen.
- a micro-structured stamp was made from PDMS (polydimethylsiloxane).
- the structures consisted of stamp feet of approx. 100 x 100 ⁇ m, which were separated by depressions 41 ⁇ m wide and five ⁇ m deep.
- the activated surface was incubated with 3% aminosilane (3-aminopropyldimethylethoxysilane; ABCR, Düsseldorf) in 10% H 2 O and 87% ethanol for 30 min.
- the silanized surface was washed first with ethanol and then with ultrapure water and blown dry with nitrogen.
- a bifunctional PEG was attached to the amino groups of the silane, one end of which had a carboxy group activated by NHS and the other end had a biotin group.
- the NHS-PEG-biotin (6 mM; Shearwater, Huntsville) was 1:20 with 6 mM NHS- methoxy-PEG 2 ooo thinned.
- a freshly prepared stamp was pressed in 1xSSC under a pressure of 125 g / cm 2 onto the spots of the support (slide). The stamp was lifted after 10 minutes. Slides and stamps were blown dry with nitrogen.
- the stamp and the slide were measured in a fluorescence scanner (Virtek, ChipReader TM; 3 ⁇ m) with a spatial resolution of 6 ⁇ m with regard to the intensity of Cy5 (excitation at 635 nm). Since a higher photomultiplier voltage was used for the measurement of the stamp than for the base, the measured intensities of the transfer to the stamp (“ABOUT”) are greater than that of the hybridization on the slide (“VOR”). Since the evaluation in the present example is based on the "OVER / BEFORE" conditions and not on a comparison of absolute measured values, the intensities could not be normalized.
- the easiest way to compare the forces is to couple a chain between two approximated surfaces and then separate the surfaces.
- the binding partners can also be immobilized on other solids, e.g. beads, or via molecules to which a tensile force can be applied.
- Coupling is the step by which a chain is linked with the two
- Case 1 corresponds to the example given above, the coupling step corresponding to the formation of the biotin-streptavidin bond between probe oligo and the stamp.
- case 2 the coupling step only takes place after the chaining has been formed, i.e. only after the sample complex and reference complex have already been linked. The only difference is that in case 1 there is coupling on the side of the reference complex and in case 2 on the side of the sample complex.
- the above exemplary embodiment describes a case in which the analyte nucleic acid or sample sequence represents the second binding partner of the sample complex and is consequently directly connected to binding partner 3, the reference sequence.
- the sample sequence takes on a "central position" within the chain.
- the sample sequence can also correspond to binding partner 1. In this case it occupies a "peripheral position" in the chain.
- the sample molecule is therefore immobilized on a surface. This is illustrated in FIG. 4.
- Cases A and B show a structure in which the sample is placed centrally ( Case A corresponds to the above exemplary embodiment.) With regard to the coupling, A can be compared with Case 1 from Figure 3 and B with Case 5 in Figure 3.
- Case 5 the sample molecule is placed peripherally and immobilized on the support Case 5 of Figure 3 comparable.
- the sample molecule can be immobilized by introducing a biotin into one of the PCR primers used to amplify the sample molecule. The binding then takes place via the binding of this biotin to the streptavidin coating of the support.
- the immobilization can also be carried out by hybridization with a capture oligo.
- the capture oligo is bound to the support and forms a complex with the sample molecule that is more stable than the reference or sample complex.
- the sample molecule is not labeled.
- the reference complex can consist of a duplex of nucleic acids or also a complex of any other binding partner, e.g. Partners of a specifically binding couple.
- reference complexes are preferably chosen that are similar to the sample complex in chemistry, base composition and GC content.
- reference complexes can also be used which differ in length and base composition compared to the sample complex, the conditions given above with regard to the free base pairing energy then having to be taken into account.
- the reference sequence is part of the sample molecule. However, this would not be the case with a peripheral position of the sample molecule.
- the reference sequence primer 2 corresponds to the amplification or the original sequence of the genomic DNA.
- the reference sequence can also consist of a sequence that was not contained on the genomic DNA and was only inserted by a degenerate primer during the amplification.
- the detection of the binding partner is done via the marking.
- the property of the detector molecule to be determined is therefore dependent on the marking used certainly. This is usually done by evaluating optical or electrical parameters.
- the use of mass spectroscopy is also possible.
- the ratio of separate sample complexes to the separate reference complexes can easily be determined from the distribution of the sample molecule between the two surfaces. In the exemplary embodiment, this would mean using only the Cy3 marker on the sample molecule.
- Q * n R ⁇ f . / N production would correspond in this case, approximately the ratio of Cy3, which is assigned to the punch to Cy3, which has remained on the slide.
- a second marker is used, which is attached to the probe and is used to determine the amount of coupled linkages (n Kop ).
- the amount of the probe marker transferred to a specific area of the stamp is compared with the sample marker transferred to the same area.
- the correct quotient is also obtained for non-reproducible coupling efficiency.
- the receptor oligo The receptor oligo
- the receptor oligonucleotide can consist of DNA, RNA, PNA, or other artificial nucleotide building blocks. As a rule, it is between 15 and 25 base pairs in length.
- a mutation is discriminated against a wild type as a rule via a difference in the quotient Q.
- two Q values are determined and compared with one another (reference experiment).
- Q W ⁇ the quotient for the wild type
- the sample molecule or the analyte nucleic acid can be both DNA and RNA as well as synthetic NA of various origins. Whether an amplification is necessary always depends on the amount of sample material available.
- the sample material is preferably amplified by PCR in order to have a sufficient amount available.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10205419 | 2002-02-09 | ||
DE2002105419 DE10205419A1 (de) | 2002-02-09 | 2002-02-09 | Verfahren zum Nachweis von Mutationen |
DE10207918 | 2002-02-23 | ||
DE2002107918 DE10207918A1 (de) | 2002-02-23 | 2002-02-23 | Verfahren zum Nachweis von Mutationen |
PCT/EP2003/001258 WO2003066896A2 (de) | 2002-02-09 | 2003-02-07 | Verfahren zum nachweis von mutationen |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1565569A2 true EP1565569A2 (de) | 2005-08-24 |
Family
ID=27735663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03737328A Withdrawn EP1565569A2 (de) | 2002-02-09 | 2003-02-07 | Verfahren zum nachweis von mutationen |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1565569A2 (de) |
AU (1) | AU2003244501A1 (de) |
WO (1) | WO2003066896A2 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10126798A1 (de) | 2001-06-01 | 2002-12-19 | Nanotype Gmbh | Verfahren zur Bestimmung einer Probe |
KR100580644B1 (ko) | 2004-02-16 | 2006-05-16 | 삼성전자주식회사 | 생물분자를 고체 기판상에 비공유적으로 고정화 하는 방법및 그에 의하여 제조되는 마이크로어레이 |
EP2390351A1 (de) | 2010-05-27 | 2011-11-30 | Centre National de la Recherche Scientifique (CNRS) | Verfahren zur DNA-Sequenzierung durch Hybridisierung |
EP2390350A1 (de) | 2010-05-27 | 2011-11-30 | Centre National de la Recherche Scientifique (CNRS) | Verfahren zur DNA-Sequenzierung durch Polymerisation |
FR2993282B1 (fr) | 2012-07-13 | 2017-11-10 | Expanscience Lab | Procede d'identification de marqueurs moleculaires de la peau d'enfant |
FR3001889B1 (fr) | 2013-02-11 | 2021-02-12 | Expanscience Lab | Utilisation d'une composition comprenant un perseose d'avocat dans la protection des cellules souches epidermiques . |
FR3011008B1 (fr) | 2013-09-24 | 2017-12-29 | Expanscience Lab | Procedes d'evaluation des effets deleteres des uv sur la peau d'enfant |
EP2886663A1 (de) | 2013-12-19 | 2015-06-24 | Centre National de la Recherche Scientifique (CNRS) | Nanoporensequenzierung mit replikativen Polymerasen und Helicasen |
FR3016373B1 (fr) | 2014-01-10 | 2018-01-19 | Laboratoires Expanscience | Modele de peau de mammelon reconstitue |
FR3019186B1 (fr) | 2014-03-31 | 2019-06-07 | Laboratoires Expanscience | Procedes d'evaluation des effets deleteres de l'urine sur la peau d'enfant |
FR3045669B1 (fr) | 2015-12-16 | 2019-04-05 | Laboratoires Expanscience | Procedes d'evaluation des effets de la deshydratation sur la peau d'enfant |
FR3053053B1 (fr) | 2016-06-23 | 2018-07-13 | Laboratoires Expanscience | Modeles de la dermatite atopique juvenile |
FR3059550B1 (fr) | 2016-12-01 | 2020-01-03 | Universite De Rouen Normandie | Traitement des troubles causes par l'alcoolisation foetale (tcaf) |
FR3068045B1 (fr) | 2017-06-22 | 2021-06-04 | Expanscience Lab | Modeles de peau sensible reconstituee |
FR3081707A1 (fr) | 2018-05-30 | 2019-12-06 | Universite De Rouen Normandie | Traitement des troubles neurologiques causes par l'alcoolisation foetale |
BR112021000934A2 (pt) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receptor para vista |
FR3091351B1 (fr) | 2018-12-27 | 2021-05-21 | Univ Rouen Centre Hospitalier | Biomarqueur de la maladie de fabry |
FR3098405B1 (fr) | 2019-07-12 | 2021-06-25 | Expanscience Lab | Composition comprenant des polyphénols de graines de passiflore, des peptides d’avocat et un extrait d’hamamélis et utilisation pour traiter et/ou prévenir les vergetures |
EP3922641A1 (de) | 2020-06-09 | 2021-12-15 | Institut Gustave-Roussy | Verfahren zum nachweis und zur behandlung von covid-patienten, die intensivpflege benötigen |
FR3133198A1 (fr) | 2022-03-04 | 2023-09-08 | Pierre Fabre Dermo-Cosmetique | Modele de peau reconstituee |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2760024B1 (fr) * | 1997-02-21 | 1999-05-14 | Centre Nat Rech Scient | Procede de caracterisation de duplex d'acide nucleique |
CA2418861A1 (en) * | 2000-08-11 | 2002-02-21 | Nanotype Gmbh | Method and device for characterising and/or for detecting a bonding complex |
-
2003
- 2003-02-07 EP EP03737328A patent/EP1565569A2/de not_active Withdrawn
- 2003-02-07 AU AU2003244501A patent/AU2003244501A1/en not_active Abandoned
- 2003-02-07 WO PCT/EP2003/001258 patent/WO2003066896A2/de not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO03066896A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003066896A3 (de) | 2004-03-25 |
WO2003066896A2 (de) | 2003-08-14 |
AU2003244501A1 (en) | 2003-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1565569A2 (de) | Verfahren zum nachweis von mutationen | |
DE69634696T2 (de) | Verfahren und testsystem zur hybridisierungsanalyse unter verwendung von peptidnukleinsäure-sonden | |
DE69633974T2 (de) | Nachweis von nukleinsäure-variationen | |
DE69932236T2 (de) | Elektrochemischer sensor unter verwendung von interkalativen, redox-aktiven teilen | |
DE112005000293B4 (de) | Verfahren zum Analysieren einer Genpolymorphie | |
DE69531831T2 (de) | Verfahren mit einer hohen umsatzrate für das auffinden von sequenzen oder genetischen veränderungen in nukleinsäuren | |
DE19935772C2 (de) | Verfahren zur relativen Quantifizierung der Methylierung von Cytosin Basen in DNA-Proben | |
DE60035691T2 (de) | Verfahren zur Erkennung von Einzel-Nukleotid-Polymorphismen | |
DE19854946C2 (de) | Klonieren und Kopieren an Oberflächen | |
EP1975246A1 (de) | Markierungsfreie Sequenzierung auf einer Festphase mittels Feldeffekttransistoren | |
DE102011055247A1 (de) | Multianalyt-Reportersystem | |
DE10214395A1 (de) | Verfahren zur Analyse von Einzelnukleotidpolymorphismen | |
DE10163599B4 (de) | Verfahren zur Bestimmung von Nukleinsäureanalyten | |
EP1186669B1 (de) | Verfahren zur spezifischen Bestimmung von DNA-Sequenzen mittels paralleler Amplifikation | |
DE19811731A1 (de) | Verfahren zum Nachweis einer Nukleotidsequenz | |
DE10259819B4 (de) | Verfahren zur PCR-Amplifikation und Detektion von Nucleotidsequenzen | |
WO2008110622A1 (de) | Verfahren und testkit zum schnellen nachweis spezifischer nukleinsäuresequenzen, insbesondere zum nachweis von mutationen oder snp's | |
WO2003052136A2 (de) | Sequenzierung über lochmembranen | |
EP1479781B1 (de) | Verfahren zum Nachweis von Nukleinsäuren | |
DE10207918A1 (de) | Verfahren zum Nachweis von Mutationen | |
DE10205419A1 (de) | Verfahren zum Nachweis von Mutationen | |
DE102005029811B4 (de) | Oligonukleotidanordnungen, Verfahren zu deren Einsatz und deren Verwendung | |
DE10161529A1 (de) | Biosensor zum Erfassen von makromolekularen Biopolymeren, Sensoranordnung mit einem Biosensor, Verfahren zur Herstellung des Biosensors und Verfahren zum Erfassen von Nukleinsäuremolekülen mittels mindestens einer Einheit zum Immobilisieren von Nukleinsäuren | |
DE60317420T2 (de) | Verfahren zu Identifizierung von Nukleotid-Polymorphismen unter Verwendung von Resonanzenergietransfer | |
DE10044543C2 (de) | Verfahren zur Bestimmung des Methylierungsgrades von bestimmten Cytosinen in genomischer DNA im Sequenzkontext 5'-CpG-3' |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
17P | Request for examination filed |
Effective date: 20050801 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ARROWHEAD RESEARCH CORPORATION |
|
17Q | First examination report despatched |
Effective date: 20060420 |
|
17Q | First examination report despatched |
Effective date: 20060420 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080306 |